Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• RiesskJ. Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape. Am J Manag Care. 2013;19(19 Suppl):s390–397.24494720
   PubMed Web of Science ®Google Scholar
• WangBY, HuangJY, ChengCY, LinCH, KoJ, LiawYP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128–1135. doi:10.1097/JTO.0b013e31829ceba423945383
   PubMed Web of Science ®Google Scholar
• YangJC, WuYL, SchulerM, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, Phase 3 trials. Lancet Oncol. 2015;16(2):141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• MokTS, WuYL, ThongprasertS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• RosellR, CarcerenyE, GervaisR, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X22285168
   PubMed Web of Science ®Google Scholar
• ImaiH, KairaK, SuzukiK, et al. A Phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer. 2018;126:41–47. doi:10.1016/j.lungcan.2018.10.01430527191
   PubMed Web of Science ®Google Scholar
• AsamiK, KoizumiT, HiraiK, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano lung cancer research group study. Clin Lung Cancer. 2011;12(6):387–392. doi:10.1016/j.cllc.2011.02.00421729650
   PubMed Web of Science ®Google Scholar
• PassaroA, AlesiniD, PochesciA, CortesiE. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. Anticancer Agents Med Chem. 2014;14(5):646–650. doi:10.2174/18715206140514050110162423140355
   PubMed Web of Science ®Google Scholar
• WuYL, SequistLV, TanEH, et al. Afatinib as first-line treatment of older patients with egfr mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials. Clin Lung Cancer. 2018;19(4):e465–e479. doi:10.1016/j.cllc.2018.03.00929653820
   PubMed Web of Science ®Google Scholar
• MaemondoM, MinegishiY, InoueA, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7(9):1417–1422. doi:10.1097/JTO.0b013e318260de8b22895139
   PubMed Web of Science ®Google Scholar
• LilenbaumRC, CashyJ, HensingTA, YoungS, CellaD. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3(2):125–129. doi:10.1097/JTO.0b013e3181622c1718303431
   PubMed Web of Science ®Google Scholar
• HsuJC, WeiCF, YangSC, LinPC, LeeYC, LuCY. Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open. 2020;10(5):e033427. doi:10.1136/bmjopen-2019-033427
   PubMed Web of Science ®Google Scholar
• GeaterSL, XuCR, ZhouC, et al. Symptom and quality of life improvement in LUX-lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in asian patients with EGFR mutation-positive advanced non-small-cell lung cancer. J Thorac Oncol. 2015;10(6):883–889. doi:10.1097/JTO.000000000000051725933111
   PubMed Web of Science ®Google Scholar
• YangJC, HirshV, SchulerM, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342–3350. doi:10.1200/JCO.2012.46.176423816967
   PubMed Web of Science ®Google Scholar
• ChenG, FengJ, ZhouC, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a Phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24(6):1615–1622. doi:10.1093/annonc/mdt01223456778
   PubMed Web of Science ®Google Scholar
• ThongprasertS, DuffieldE, SaijoN, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6(11):1872–1880. doi:10.1097/JTO.0b013e31822adaf722011650
   PubMed Web of Science ®Google Scholar
• BeckettP, CallisterM, TataLJ, et al. Clinical management of older people with non-small cell lung cancer in England. Thorax. 2012;67(9):836–839. doi:10.1136/thoraxjnl-2011-20099422771514
   PubMed Web of Science ®Google Scholar
• EttingerDS, WoodDE, AisnerDL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi:10.6004/jnccn.2021.001333668021
   PubMed Web of Science ®Google Scholar
• SpigelDR, LinM, O’NeillV, HainsworthJD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 2008;112(12):2749–2755. doi:10.1002/cncr.2349018438878
   PubMed Web of Science ®Google Scholar
• ThatcherN, ChangA, ParikhP, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet. 2005;366(9496):1527–1537. doi:10.1016/S0140-6736(05)67625-816257339
   PubMed Web of Science ®Google Scholar
• KimC, LiuSV. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Ann Oncol. 2019;30(12):1852–1855. doi:10.1093/annonc/mdz41531613313
   PubMed Web of Science ®Google Scholar
• SehgalK, GillRR, WidickP, et al. Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open. 2021;4(2):e2037120. doi:10.1001/jamanetworkopen.2020.3712033570575
   PubMed Web of Science ®Google Scholar
• Dall’OlioFG, MaggioI, MassucciM, MollicaV, FragomenoB, ArdizzoniA. ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95–104. doi:10.1016/j.lungcan.2020.04.02732417680
   PubMed Web of Science ®Google Scholar
• OhY, TaylorS, BekeleBN, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115(13):2930–2938. doi:10.1002/cncr.2433319441110
   PubMed Web of Science ®Google Scholar
• ParkJH, KimTM, KeamB, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin Lung Cancer. 2013;14(4):383–389. doi:10.1016/j.cllc.2012.10.00723313171
   PubMed Web of Science ®Google Scholar
• ProtoC, ImbimboM, GallucciR, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res. 2016;5(6):563–578. doi:10.21037/tlcr.2016.10.1628149752
   PubMed Web of Science ®Google Scholar
• IuchiT, ShingyojiM, ItakuraM, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2015;20(4):674–679. doi:10.1007/s10147-014-0760-925336382
   PubMed Web of Science ®Google Scholar
• ChenYH, ChenYF, ChenCY, ShihJY, YuCJ. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer. 2019;19(1):1006. doi:10.1186/s12885-019-6140-031655564
   PubMed Web of Science ®Google Scholar
• SuPL, WuYL, ChangWY, et al. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758835918797589. doi:10.1177/175883591879758930263066
   PubMed Web of Science ®Google Scholar
• ChangYP, ChenYM, LaiCH, et al. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS One. 2017;12(6):e0178676. doi:10.1371/journal.pone.017867628591157
   PubMed Web of Science ®Google Scholar
• WuKL, TsaiMJ, YangCJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88(2):187–194. doi:10.1016/j.lungcan.2015.02.01225747806
   PubMed Web of Science ®Google Scholar
• SuVY, YangKY, HuangTY, et al. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Sci Rep. 2020;10(1):14965. doi:10.1038/s41598-020-71583-w32917914
   PubMed Web of Science ®Google Scholar
• HsiehYY, FangWT, LoYW, ChenYH, ChienLN. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: a retrospective cohort study in Taiwan. Int J Cancer. 2020;147(4):1107–1116. doi:10.1002/ijc.3284131854456
   PubMed Web of Science ®Google Scholar
• ChangCY, LaiYC, WeiYF, ChenCY, ChangSC. PD-L1 expression and outcome in patients with metastatic non-small cell lung cancer and EGFR mutations receiving EGFR-TKI as frontline treatment. Onco Targets Ther. 2021;14:2301–2309. doi:10.2147/OTT.S29044533833528
   PubMed Web of Science ®Google Scholar
• SoriaJC, OheY, VansteenkisteJ, et al. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa171313729151359
   PubMed Web of Science ®Google Scholar
• NakashimaK, KimuraM, AkamatsuH, et al. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol. 2019;49(7):671–675. doi:10.1093/jjco/hyz04130920616
   PubMed Web of Science ®Google Scholar